Judging Category
Basic or Experimental Research
Student Rank
Graduate
College
University College
Faculty Sponsor
Dr. Natarajan Ganesan email: nganesan@nyit.edu
Description
Glioblastoma (GBM) is one of the deadliest and most common brain tumor which remains highly resistant to temozolomide (TMZ), contributing to poor patient outcomes. Literature suggests that sertraline, a widely used SSRI, disrupts mitochondrial metabolism in cancer cells. Because GBM depends heavily on succinate dehydrogenase (SDH) for oxidative phosphorylation, sertraline‑mediated SDH inhibition may increase metabolic stress and reduce functional TMZ resistance. This poster presents a literature‑based rationale and proposed experimental design to evaluate sertraline‑induced SDH modulation and its potential to sensitize TMZ‑resistant T98G glioblastoma cells. These findings will guide future experimental work.
Disciplines
Biochemical Phenomena, Metabolism, and Nutrition | Chemical and Pharmacologic Phenomena | Medical Biochemistry | Medical Cell Biology | Medical Neurobiology | Medical Physiology | Medical Sciences | Neurology | Neurosciences | Oncology
License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Recommended Citation
Mallapuram, Supraja, "Investigating Sertraline‑Mediated Modulation of Succinate Dehydrogenase to Sensitize TMZ‑Resistant Glioblastoma Cells" (2026). Create@State. 37.
https://arch.astate.edu/evn-createstate/2026/posters/37
Included in
Biochemical Phenomena, Metabolism, and Nutrition Commons, Chemical and Pharmacologic Phenomena Commons, Medical Biochemistry Commons, Medical Cell Biology Commons, Medical Neurobiology Commons, Medical Physiology Commons, Neurology Commons, Neurosciences Commons, Oncology Commons
Investigating Sertraline‑Mediated Modulation of Succinate Dehydrogenase to Sensitize TMZ‑Resistant Glioblastoma Cells
Glioblastoma (GBM) is one of the deadliest and most common brain tumor which remains highly resistant to temozolomide (TMZ), contributing to poor patient outcomes. Literature suggests that sertraline, a widely used SSRI, disrupts mitochondrial metabolism in cancer cells. Because GBM depends heavily on succinate dehydrogenase (SDH) for oxidative phosphorylation, sertraline‑mediated SDH inhibition may increase metabolic stress and reduce functional TMZ resistance. This poster presents a literature‑based rationale and proposed experimental design to evaluate sertraline‑induced SDH modulation and its potential to sensitize TMZ‑resistant T98G glioblastoma cells. These findings will guide future experimental work.
